Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Medical Oncology and Gastroenterology Department, Service Inter-Hospitalier de Cancérologie, Hôpital Beaujon and Paris Diderot University, Clichy; Cancer Care, Institut Paoli-Calmettes, and RENATEN Network, Marseille, France; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; Medical Oncology Department, The University of Manchester/The Christie NHS Foundation Trust, Manchester, UK; Translational Medicine – Digestive Cancers, Institut Paoli-Calmettes and RENATEN Network, Marseille, France; Eastern Virginia Medical School Streilitz Diabetes Research Center and Neuroendocrine Unit, Norfolk, USA; Digestive Oncology Unit, University Hospitals Leuven and KU Leuven, Leuven, Belgium; Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Hepato-Gastroenterology Unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Medical Oncology Department, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; McGill University Hospital Centre, Montreal, Canada; Oncology Department, University Hospital, Bordeaux, France; Linkou Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan; Centre Hospitalier Universitaire Timone, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille Université, and RENATEN Network, Marseille, France; Pfizer Oncology, La Jolla, USA; Department of Evidera, St-Laurent, Canada

[1]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[3]  E. D. de Vries,et al.  Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[5]  D. Sargent,et al.  Blinded independent central review of the progression-free survival endpoint. , 2010, The oncologist.

[6]  N. Pryer,et al.  SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. , 2003, Molecular cancer therapeutics.

[7]  L. Sobin,et al.  Histological Typing of Endocrine Tumours , 2000, International Histological Classification of Tumours.

[8]  J. Robins,et al.  Correcting for non-compliance in randomized trials using rank preserving structural failure time models , 1991 .

[9]  Y. Bang,et al.  Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET). , 2012 .

[10]  S. Faivre,et al.  Methods for Adjusting for Bias Due to Crossover in Oncology Trials , 2014, PharmacoEconomics.

[11]  David Goldstein,et al.  Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure , 2012, Clinical Cancer Research.

[12]  E. Raymond,et al.  Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. , 2010, Endocrinology and metabolism clinics of North America.

[13]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Casey,et al.  Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial , 2010, The oncologist.

[15]  J. Zietsman.  May, 2007 , 2007, The Lancet Neurology.

[16]  Norbert Hollaender,et al.  Phase 3 trial of everolimus for metastatic renal cell carcinoma , 2010, Cancer.

[17]  L. Tye,et al.  Activity of sunitinib in patients with advanced neuroendocrine tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Hanahan,et al.  VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. , 2002, Cancer cell.

[19]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  H. Tsuda,et al.  Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3 , 2011, Breast Cancer Research.